277 related articles for article (PubMed ID: 35263486)
1. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x
Negi A; Voisin-Chiret AS
Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486
[TBL] [Abstract][Full Text] [Related]
2. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
[TBL] [Abstract][Full Text] [Related]
3. Discovery of IAP-recruiting BCL-X
Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
[TBL] [Abstract][Full Text] [Related]
4. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
He Y; Zhang X; Chang J; Kim HN; Zhang P; Wang Y; Khan S; Liu X; Zhang X; Lv D; Song L; Li W; Thummuri D; Yuan Y; Wiegand JS; Ortiz YT; Budamagunta V; Elisseeff JH; Campisi J; Almeida M; Zheng G; Zhou D
Nat Commun; 2020 Apr; 11(1):1996. PubMed ID: 32332723
[TBL] [Abstract][Full Text] [Related]
5. Discovery of PROTAC BCL-X
Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
Jia Y; Han L; Ramage CL; Wang Z; Weng CC; Yang L; Colla S; Ma H; Zhang W; Andreeff M; Daver N; Jain N; Pemmaraju N; Bhalla K; Mustjoki S; Zhang P; Zheng G; Zhou D; Zhang Q; Konopleva M
Haematologica; 2023 Oct; 108(10):2626-2638. PubMed ID: 37078252
[TBL] [Abstract][Full Text] [Related]
7. A selective BCL-X
Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D
Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a Novel BCL-X
Pal P; Thummuri D; Lv D; Liu X; Zhang P; Hu W; Poddar SK; Hua N; Khan S; Yuan Y; Zhang X; Zhou D; Zheng G
J Med Chem; 2021 Oct; 64(19):14230-14246. PubMed ID: 34533954
[TBL] [Abstract][Full Text] [Related]
9. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.
Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
Cells; 2024 Mar; 13(6):. PubMed ID: 38534371
[TBL] [Abstract][Full Text] [Related]
10. PROTACs are effective in addressing the platelet toxicity associated with BCL-X
Zhang P; Zhang X; Liu X; Khan S; Zhou D; Zheng G
Explor Target Antitumor Ther; 2020; 1(4):259-272. PubMed ID: 34296214
[TBL] [Abstract][Full Text] [Related]
11. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.
Wang C; Zhang Y; Shi L; Yang S; Chang J; Zhong Y; Li Q; Xing D
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1437-1453. PubMed ID: 35589670
[TBL] [Abstract][Full Text] [Related]
13. PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer.
Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
bioRxiv; 2024 Mar; ():. PubMed ID: 38464204
[TBL] [Abstract][Full Text] [Related]
14. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer.
Wei Y; Zhang L; Wang C; Li Z; Luo M; Xie G; Yang X; Li M; Ren S; Zhao D; Gao R; Gong JN
Animal Model Exp Med; 2023 Jun; 6(3):245-254. PubMed ID: 37271936
[TBL] [Abstract][Full Text] [Related]
15. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X
Zhang X; Thummuri D; He Y; Liu X; Zhang P; Zhou D; Zheng G
Chem Commun (Camb); 2019 Dec; 55(98):14765-14768. PubMed ID: 31754664
[TBL] [Abstract][Full Text] [Related]
16. The PROTAC selectively degrading Bcl-x
Zhang S; Chen Y; Xu Z; Yang J; Sun R; Wang J; Sun Y; Jiang B; Yang X; Tan W
Theranostics; 2022; 12(17):7476-7490. PubMed ID: 36438482
[No Abstract] [Full Text] [Related]
17. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
[TBL] [Abstract][Full Text] [Related]
18. Structural Insights into PROTAC-Mediated Degradation of Bcl-xL.
Chung CW; Dai H; Fernandez E; Tinworth CP; Churcher I; Cryan J; Denyer J; Harling JD; Konopacka A; Queisser MA; Tame CJ; Watt G; Jiang F; Qian D; Benowitz AB
ACS Chem Biol; 2020 Sep; 15(9):2316-2323. PubMed ID: 32697072
[TBL] [Abstract][Full Text] [Related]
19. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
Ohoka N
Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
[TBL] [Abstract][Full Text] [Related]
20. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
